Internal Medicine, Infectious Disease · Metairie, LA
NPI
1356447635
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
4315 Houma Blvd Ste 201
Metairie, LA, 70006
Phone (504) 455-4622
Groups this clinician bills Medicare through
Medicare paid, 2024
$119K
1,340 services
Medicare patients, 2024
238
Average age 75
Drug cost, 2024
$1.3M
924 prescriptions
Company payments, 2025
$2,476
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John M Depaula was code 99232 (hospital e&m - subsequent), 424 times for 130 patients. In total John M Depaula billed 1,340 services in 21 codes, and Medicare paid $119K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-09-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 424 | 130 | $57.92 | $25K |
| 99233 Hospital E&M - Subsequent | Facility | 387 | 124 | $87.36 | $34K |
| 99223 Hospital E&M - Initial | Facility | 169 | 133 | $127.06 | $21K |
| 99291 Critical Care E&M | Facility | 139 | 27 | $157.48 | $22K |
| 99309 SNF E&M | Facility | 63 | 19 | $79.20 | $4,989 |
| 99215 Office E&M - Established | Office | 47 | 33 | $123.39 | $5,800 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 28 | 17 | $11.71 | $328 |
| 99214 Office E&M - Established | Office | 25 | 21 | $89.85 | $2,246 |
| 99308 SNF E&M | Facility | 24 | 11 | $54.66 | $1,312 |
By year: 2022 $150K for 1,571 services; 2023 $100K for 1,058 services; 2024 $119K for 1,340 services.
Medicare prescription drug claims, 2024
In 2024, the drug John M Depaula prescribed most often to Medicare patients was Dovato (Dolutegravir Sodium/Lamivudine), with 91 prescriptions and refills. In total John M Depaula wrote 924 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dovato Dolutegravir Sodium/Lamivudine | 91 | 91 | Under 11 | $273K |
| Azithromycin Generic | 91 | 112 | 18 | $1,663 |
| Ethambutol Hcl Generic | 51 | 63 | 15 | $3,835 |
| Ciprofloxacin Hcl Generic | 43 | 52 | 19 | $482 |
| Doxycycline Hyclate Generic | 33 | 39 | 16 | $423 |
| Rifabutin Generic | 32 | 33 | Under 11 | $17K |
| Arikayce Amikacin Liposomal/Neb.Accessr | 30 | 31 | Under 11 | $454K |
| Cefdinir Generic | 29 | 42 | 18 | $592 |
| Valacyclovir Valacyclovir Hcl | 23 | 35 | Under 11 | $1,201 |
| Rifampin Generic | 22 | 36 | Under 11 | $1,913 |
| Meropenem Generic | 21 | 21 | Under 11 | $2,494 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 21 | 25 | 12 | $261 |
| Ceftriaxone Ceftriaxone Sodium | 21 | 21 | Under 11 | $1,389 |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 19 | 19 | Under 11 | $93K |
| Tivicay Dolutegravir Sodium | 19 | 19 | Under 11 | $60K |
Brand drugs: 256 claims; generic drugs: 668 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John M Depaula $2,476 ($2,476 in general payments such as food, travel and fees) from 14 companies. The largest payer was ViiV Healthcare Company with $746.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 35 | $746 |
| Abbvie Inc. ABBV | 18 | $291 |
| Theratechnologies Inc. THTX | 7 | $279 |
| Gilead Sciences, Inc. GILD | 13 | $261 |
| Paratek Pharmaceuticals, Inc. | 16 | $206 |
| Insmed, Inc. INSM | 9 | $193 |
| Merck Sharp & Dohme LLC MRK | 9 | $179 |
| Astellas Pharma US Inc 4503.T | 4 | $110 |
| Pfizer Inc. PFE | 3 | $49.26 |
| Melinta Therapeutics, LLC | 2 | $42.55 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.